Price movement over the last 24 hours
Abeona Therapeutics Inc vs Direxion Daily Semiconductor Bear 3X Shares — how do they compare? Abeona Therapeutics Inc trades at $6.74 (market cap $373.32M), while Direxion Daily Semiconductor Bear 3X Shares trades at $4.56. The key difference: Abeona Therapeutics Inc is trading nearer its 52-week high, Direxion Daily Semiconductor Bear 3X Shares nearer its low. Which is the better fit depends on your goals.
| ABEO | SOXS | |
|---|---|---|
Market Cap | $373.32M | — |
Sector | Health | Leveraged / Inverse |
52-Week High | $7.23 | $160.60 |
52-Week Low | $4.17 | $3.25 |
Enterprise Value | $228.22M | — |
Signals from Pluang's Aura AI — not financial advice
ABEO trades at $6.31, down 1.41% today, with a bullish technical outlook supported by moving averages. The company reported Q1 2026 results with revenue growth and beat EPS expectations, while maintaining strong profitability margins. Recent news highlights expansion of treatment centers and new cell therapy licensing.
Outlook remains positive with analyst consensus favoring Buy ratings (66.67%), though high RSI indicates potential near-term overbought conditions. Key risks include negative operating cash flow and reliance on new treatment adoption. Upside depends on continued commercial execution and pipeline advancements.
SOXS, the Direxion Daily Semiconductor Bear 3X Shares ETF, is trading at $4.17, down 7.54% over the past 24 hours. The technical outlook is bearish, with moving averages signaling a downtrend and oscillators neutral. A 1-for-10 stock split is scheduled for July 15, 2026. Recent news highlights the ETF's role in betting against the semiconductor sector amid a historic AI-driven chip rally, with SOXS down 88% over six months as of May 2026.
The outlook for SOXS remains highly risky due to its inverse leveraged structure and the strong bullish trend in semiconductors. Investment opportunity exists solely for tactical, short-term traders seeking to profit from potential sector pullbacks, but risks of significant losses are elevated if the rally persists. Long-term investors should avoid due to volatility decay and structural drawbacks.
Trailing returns across standard periods
Latest headlines on both assets
Abeona Therapeutics develops gene and cell therapies for rare diseases. Its lead product, ZEVASKYN, is an FDA-approved therapy for recessive dystrophic epidermolysis bullosa (RDEB), a severe and life-threatening genetic skin disorder.
Read more on ABEO →SOXS is a leveraged ETF that seeks daily investment results corresponding to 300% of the inverse (opposite) of the daily performance of the ICE Semiconductor Index. It is designed as a tactical tool for experienced traders to take a bearish (short) position on the semiconductor sector. Due to the effects of compounding and leverage, SOXS is intended to be held for a single day and is not suitable for long-term investment.
Read more on SOXS →